Cited by 66Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsDiabetes, Cardiovascular Risks, and Lipoproteins

Brain glucose metabolism in health, obesity, and cognitive decline-does insulin have anything to do with it? A narrative review

Open access
Rebelos, Eleni, Rinne, Juha O., Nuutila, Pirjo, Ekblad, Laura L.·2021·Journal of Clinical Medicine

Abstract

Imaging brain glucose metabolism with fluorine-labelled fluorodeoxyglucose ([18F]-FDG) positron emission tomography (PET) has long been utilized to aid the diagnosis of memory disorders, in particular in differentiating Alzheimer’s disease (AD) from other neurological conditions causing cognitive decline. The interest for studying brain glucose metabolism in the context of metabolic disorders has arisen more recently. Obesity and type 2 diabetes—two diseases characterized by systemic insulin resistance—are associated with an increased risk for AD. Along with the well-defined patterns of fasting [18F]-FDG-PET changes that occur in AD, recent evidence has shown alterations in fasting and insulin-stimulated brain glucose metabolism also in obesity and systemic insulin resistance. Thus, it is important to clarify whether changes in brain glucose metabolism are just an epiphenomenon of the pathophysiology of the metabolic and neurologic disorders, or a crucial determinant of their pathophysiologic cascade. In this review, we discuss the current knowledge regarding alterations in brain glucose metabolism, studied with [18F]-FDG-PET from metabolic disorders to AD, with a special focus on how manipulation of insulin levels affects brain glucose metabolism in health and in systemic insulin resistance. A better understanding of alterations in brain glucose metabolism in health, obesity, and neurodegeneration, and the relationships between insulin resistance and central nervous system glucose metabolism may be an important step for the battle against metabolic and cognitive disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm10071532

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Brain glucose transport and metabolism can be both increased or decreased by obesity, depending upon the structure under investigation.

    “Brain glucose transport and metabolism can be both increased or decreased by obesity, depending upon the structure under investigation [59].”

    From The menace of obesity to depression and anxiety prevalence (2022) · cites this paper as [59]

  • Reductions in glucose uptake in the hippocampus have been connected to cognitive deficits in obesity.

    “Reductions in glucose uptake in the hippocampus have been connected to cognitive deficits in obesity [59].”

    From The menace of obesity to depression and anxiety prevalence (2022) · cites this paper as [59]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rebelos, E., Rinne, J. O., Nuutila, P., & Ekblad, L. L.
Affiliations
University of Turku (FI)
Corresponding author
Ekblad, Laura L.
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2021-04-06
Volume
10
Issue
7
Pages
1532
ISSN
2077-0383 (ISSN-L)
OpenAlex
W3141113378
Cited by
66
References
114
Citations by year
2026: 11 · 2025: 9 · 2024: 13 · 2023: 16 · 2022: 13 · 2021: 4
FWCI
2.05
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UTUPub (University of Turku) (submittedVersion, cc-by)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • European Foundation for the Study of Diabetes
  • Suomen Kulttuurirahasto
  • Emil Aaltosen Säätiö
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
brain glucose metabolism, insulin resistance, obesity, type 2 diabetes, Alzheimer's disease, cognitive decline, 18F-FDG PET, insulin-stimulated glucose metabolism, metabolic disorders, neurodegeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review